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Background and objectives: Nonadherence to oral immunosuppressive drugs in renal 
transplant patients remains a major challenge. The objective of this study was to develop an 
adherence-exposure model that 1) quantifies the impact of nonadherence patterns on cyclosporine 
levels and 2) identifies nonadherence patterns that are associated with unfavorable transplantation 
outcomes.
Design, setting, participants, and measurements: This model quantified variability in 
drug exposure, expressed as the coefficient of variation (CV%), for time-averaged and trough 
cyclosporine levels (Cavg and Cmin, respectively), and percentage of days spent below the 
therapeutic Cmin target. Simulated patterns of nonadherence closely matched those observed in 
clinical practice for four nonadherence clusters and an “Others” category.
Results: Patients in simulated nonadherence clusters 1–3 spent a mean (standard deviation) 5.8% 
(4.9), 9.0% (5.0), and 6.5% (3.4) of days below the Cmin target, compared with 76.8% (6.5) for 
cluster 4 and 38.3% (6.4) for the “Others” category. Mean (standard deviation) CV% values for 
Cmin were 24.1 (7.9), 35.4 (11.7), and 34.1 (10.6) for clusters 1–3, compared with 136.4 (23.6) 
for cluster 4 and 64.8 (10.3) for the “Others” category. Findings for Cavg were similar.
Conclusion: Based on nonadherence patterns and known relationships between CV% for 
Cmin and Cavg, and transplantation outcomes, patients in cluster 4 and the “Others” category are 
expected to be at high risk of allograft rejection. The proposed drug adherence-exposure model 
is useful to identify high-risk patients who can be targeted for interventions aimed at enhancing 
drug adherence to optimize clinical long-term outcomes.
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Introduction
While long-term adherence to therapy has clear benefits in many illnesses, organ 
transplantation stands out as one of the few medical conditions where the implications 
of suboptimal adherence are as significant as allograft rejection, a return to dialysis, 
and potentially death. Immunosuppressive regimens have long been dominated by the 
calcineurin inhibitors, such as cyclosporine and its derivatives. Cyclosporine, which is 
taken orally at intervals of 12 hours, requires drug monitoring and dose adjustment to 
maintain serum concentration levels (exposure) within a narrow therapeutic range.1
The measure most widely used in practice to monitor cyclosporine exposure for the 
purpose of dose adjustment is the trough concentration, Cmin, the serum level 12 hours 
after a first dose and immediately before the next dose. Although the serum level at 
2 hours correlates better with Cavg, the time-averaged cyclosporine concentration 
during the 12-hour period between doses, the trough level is thought to be the most Therapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
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practical measure of exposure.1,2 To maintain effective 
immunosuppression, Cmin values must be maintained above a 
floor of 100–200 ng/mL (the value defined in the US product 
label for the microemulsion formulation of cyclosporine). 
Figure 1 illustrates that after cyclosporine dose is adjusted 
to a trough of 100–200 ng/mL, the serum concentration will 
fall below that level if the next dose is delayed or missed.3 In 
contrast, over-exposure to high serum levels of cyclosporine 
is nephrotoxic, but the threshold at which this takes effect 
has not been clearly defined.
After dose optimization, within-patient variability in 
cyclosporine exposure persists and is associated with higher 
rates of adverse transplantation outcomes.4,5 Variability in 
cyclosporine exposure is described by the coefficient of varia-
tion (CV%), which is the standard deviation expressed as a 
percentage of the mean of the measure of exposure (either 
Cmin or Cavg). Kahan et al determined that patients above a 
CV% $ 28.4% in Cavg for cyclosporine had an increased 
5-year incidence of chronic rejection (40%, compared with 
24% for patients below the threshold).4 A CV% value for Cmin 
above a threshold of 36% was similarly associated with an 
increased risk of chronic rejection.4 In a similar 5-year study, 
Waiser et al determined a CV% threshold for Cmin of   28.05%.5 
Compared with patients with a CV% below this threshold, 
those above experienced a higher incidence of acute rejection 
(40.7% versus 29.4%), a lower rate of graft survival (81.1% 
versus 93.3%), and higher serum creatinine levels (1.7 versus 
1.4 mg/dL; P , 0.05 for all comparisons).5
One major cause of variability in drug exposure is 
nonadherence.6 Nonadherence remains a major challenge in 
the provision of medical care, particularly in the management of 
chronic conditions outside of the confines of a clinical trial, and 
where a medicine’s positive and negative attributes interface 
with day-to-day human health behaviors. Thus, between 14% 
and 65% (interquartile range) of renal graft losses have been 
attributed to nonadherence in cohort studies.7 However, the 
level of nonadherence that increases the risk of renal graft 
failure has not been identified7 and estimates of the prevalence 
of nonadherence to oral immunosuppressive drugs in renal 
transplant patients vary widely, from 2% to 67%.8 In their 
systematic review, Butler et al reported that nonadherence was 
formally defined in only 10 of 37 studies analyzed.7 Consensus 
on a threshold defining nonadherence did not exist.7
Studies using the Medication Event Monitoring System 
(MEMS) find that patients’ medication-taking behavior 
comprises a variety of complex patterns that cannot clearly 
be dichotomized into adherent and nonadherent.9 Russell 
et al used MEMS to study adult kidney transplant recipients 
taking an oral immunosuppressant twice daily at prescribed 
times, 12 hours apart, in the morning and evening.9 At 
each dosing, one of four possibilities could occur: the dose 
could be taken early, on time, late, or could be missed. “On 
time” was defined as a dose within 1.5 hours on either side 
of the target time, and early and late doses fell outside the 
window of ±1.5 hours but within ±6.0 hours. The unit of 
analysis was day, and because there were four outcomes at 
each of the two doses on a day, there were 16 (42) possible 
adherence patterns. A patient’s adherence was described 
in terms of the proportion of the total study days the 
patient’s medication-taking fell into each of the 16 possible 
adherence patterns. Russell et al applied cluster analysis 
to the adherence patterns and observed four statistically 
homogeneous clusters of subjects and an “Others” category 
in which patients did not cluster into a single pattern of 
behavior. Figure 2A reproduces the distributions of each 
of the 16 adherence patterns observed by Russell et al for 
patients in clusters 1–4. Patients in cluster 1 (32%) almost 
always took both daily doses of their medication on time. 
Those in cluster 2 (18%) sometimes missed doses or were 
late, those in cluster 3 (14%) were frequently late with one 
or both daily doses, and those in cluster 4 (9%) most often 
missed both doses. Twenty-seven percent of patients fell into 
the heterogeneous “Other” category.
There was, however, no known relationship between the 
complex patterns of nonadherence reported by Russell et al 
and immunosuppressant exposure – and hence transplantation 
outcomes. Relationships between nonadherence patterns and 
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Figure 1 Cyclosporine serum concentration following drug titration targeting a 
trough concentration of 100–200 ng/mL. shown is the median (solid line) and 90% 
population  exposure  range  (shaded  area)  of  cyclosporine  serum  concentration 
following a dose adjusted to a target trough concentration of 100–200 ng/mL. 
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Figure 2 A) Observed distributions of nonadherence patterns in renal transplant patients. shown are nonadherence patterns observed by Russell et al9 for patients in 
clusters 1–4 (ns 14, 8, 6, and 4, respectively; the “Others” category, n = 12, is not presented). each line represents an individual patient. The ordinate shows the percent 
days with each adherence pattern, and the abscissa shows the 16 patterns, numbered 0–15; the top row of abbreviations shows the timing of morning dose, and the bottom 
row, timing of the evening dose. B) simulated distributions of nonadherence patterns. 
Figure 2A was reprinted with permission of John Wiley & sons, inc. from Res nurs health vol. 29, no. 6, 2006, pp. 521–532.
Abbreviations: OT, on time; e, early; L, late; M, missed. Therapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
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drug exposure can be characterized by computer modeling, 
an approach pioneered by LB Sheiner.6 We sought to 
characterize the link between the attributes of a medicine, 
patient medicine-taking behavior, and drug exposure 
by adapting the “dose-adherence-exposure-outcomes” 
framework described by LB Sheiner to a case study in kidney 
transplantation (Figure 3). Here we develop a drug adherence-
exposure model that 1) characterizes nonadherence patterns 
to twice-daily oral immunosuppressants, 2) quantifies their 
impact on exposure to cyclosporine, expressed as CV% for 
Cavg and Cmin, and as the proportion of days spent below the 
cyclosporine floor value of 100 ng/mL, and 3) identifies 
nonadherence patterns that are associated with unfavorable 
transplantation outcomes such as increased risk of allograft 
rejection. The goal was to propose a drug adherence-exposure 
model than can be used to identify high-risk patients who 
could be targeted for interventions aimed at enhancing drug 
adherence, hence reducing the risks of allograft rejection, 
a return to dialysis, and death.
Materials and methods
The impact of drug nonadherence on the within- and between-
individual variability of cyclosporine exposure was quantified 
by coupling a model of adherence to a dose-exposure model. 
The adherence model was developed to mimic the 16 nonadher-
ence patterns described by Russell et al.9 This adherence model 
was coupled to a previously published population pharmacoki-
netic (dose-exposure) model that describes the within- and 
between-individual variability in the concentration-time profile 
of cyclosporine.3 The coupled simulation model was applied 
to determine variability in two measures of exposure: Cavg 
and Cmin. The drug adherence model was developed in S-PLUS 
and the cyclosporine   population   pharmacokinetic (nonlinear 
mixed-effects) model was implemented in NONMEM®.10,11 
The structural component of the population pharmacokinetic 
model was specified as a one-compartment model with 
first-  order absorption, with typical values   structural model 
parameters specified by fixed-effect parameters, and between-
individual variability in structural model parameter values 
specified by random-effects parameters.
The combined effect of nonadherence and pharma-
cokinetic characteristics on variability in cyclosporine 
concentrations was determined by applying the coupled 
drug adherence and drug-exposure models to simulate Cavg 
and Cmin values for 500 patients over a period of 90 days 
(a total of 45,000 patient-days). There were four steps to 
the procedure used to simulate the cyclosporine exposures 
for each subject (  Figure 3): 1) assign a dose to the subject; 
2) simulate a sequence of doses for the subject by applying 
the adherence model; 3) simulate Cavg and Cmin values for each 
dose, by applying the dose-exposure model; and 4) calculate 
within-subject variability in Cavg and Cmin values and assess 
implications of variability on clinical outcome.
First, steady-state Cmin values were simulated for each 
of 500 subjects with the population pharmacokinetic model, 
assuming perfect adherence to the recommended dose of 
cyclosporine. The dose of cyclosporine assigned to each 
subject was adjusted such that the steady-state Cmin value 
for the subject was within the widely accepted therapeutic 
window of 100–200 ng/mL for immunosuppression 
maintenance. Second, the drug adherence model was applied 
to simulate a sequence of doses for each of the 500 subjects 
over a period of 90 days, based upon the relative frequency 
of the adherence patterns reported by Russell et al.9 Third, 
the population pharmacokinetic model was used to simulate 
Cavg and Cmin values for each dose in a sequence for each 
of the 500 subjects. The variability in the values of Cavg 
and Cmin were then summarized and reported. Finally, the 
within-subject CV% was calculated for the simulated Cavg 
and Cmin values, and subjects with excessive variability were 
identified, based on threshold levels of variability reported 
by Kahan et al and Waiser et al.4,5
Based on the frequencies of the 16 nonadherence patterns 
observed by Russell et al,9 the 45,000 patient-days were 
distributed as follows: 20,995 to pattern 0, 630 to pattern 1, 
3,946 to pattern 2, 486 to pattern 3, 3,362 to pattern 4, etc. 
Of the 500 patients, 159 were assigned to cluster 1, 91 to 
cluster 2, 91 to cluster 3, 45 to cluster 4, and 114 to the 
“Others” category. Adherence patterns were simulated for 
each individual patient. For patient 1 of cluster 1, the 16 
patterns of dosing were assigned as follows: patterns 0, 2, 
4, 10, and 15 were assigned 76 days, 2 days, 6 days, 1 day, 
and 5 days, respectively. These patterns were randomly 
Dose Adherence Exposure Outcome
Figure 3 The drug adherence-exposure model. The diagram shows the conceptual 
framework  of  the  drug  adherence-exposure  model  rather  than  the  temporal 
sequence of events. The impact of drug nonadherence patterns on the within- and 
between-individual variability of cyclosporine exposure was quantified by coupling a 
model of adherence to a dose-exposure model. An adherence model was developed 
to mimic the 16 nonadherence patterns described by Russell et al,9 and this adherence 
model was coupled to a previously published population pharmacokinetic (dose-
exposure) model for cyclosporine.3 The combined effect of nonadherence patterns 
and pharmacokinetic characteristics on variability in cyclosporine concentrations 
was quantified by applying the coupled drug adherence and drug-exposure models 
to simulate Cavg and Cmin values for 500 patients over a period of 90 days (a total 
of 45,000 patient-days). Subjects with excessive variability were identified based on 
threshold levels of variability reported by Kahan et al and Waiser et al.4,5 individual 
patients at risk of adverse transplantation outcomes can thus be identified by their 
nonadherence behavior. 
Abbreviations: Cavg, average cyclosporine levels; Cmin, trough cyclosporine levels.Therapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
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reshuffled to generate dosing over 90 days for patient 1. 
This process was repeated for patient 2 of cluster 1 after 
subtracting from the total sum of 45,000 adherence patterns 
those already completed by patient 1 (ie, 41,994 minus 76 for 
pattern 0, 7,893 minus 2 for pattern 2, etc.). This process was 
repeated for the remaining patients in cluster 1, and then for 
the patients in clusters 2–4. After subtracting all patients in 
clusters 1–4 from the total, there remained 114 patients with 
N0 in pattern 0, N1 in pattern 1, etc, in the “Others” category. 
For subject 1 in this category, a weighted random sampling 
was taken from the remaining patterns. This process was 
repeated for the remaining subjects.
Results
simulated adherence patterns
Figure 2B shows the simulated distributions of adherence 
patterns computed by the drug adherence-exposure model. 
These calculated distributions are essentially superimposable 
on the distributions observed by Russell et al.
Variability in cyclosporine exposure  
by simulated adherence cluster
Distributions of CV% values for Cavg are presented in   Figure 4 
for the simulated adherence clusters. The distributions for 
clusters 1–3, which had mean (standard deviation [SD]) 
values of 12.0 (4.1), 17.5 (3.5), and 13.9 (3.3), respectively, 
were distinct from that of cluster 4, which had a mean (SD) 
value of 71.9 (12.8), while the “Others” distribution lay in an 
intermediate position, with mean (SD) of 35.7 (6.3). None of 
the subjects in clusters 1–3 had Cavg variability greater than 
the threshold value of 28.4% CV , whereas the percentages of 
subjects in cluster 4 and “Others” with Cavg variability above 
the threshold value were 100 and 85, respectively.
The distributions of CV% values for Cmin were similar to 
those for Cavg (Figure 5). Mean (SD) values for clusters 1–4 and 
“Others” were 24.1 (7.9), 35.4 (11.7), 34.1 (10.6), 136.4 (23.6), 
and 64.8 (10.3), respectively. The Cmin variability of most 
subjects in clusters 1–3 (8%–24%) was less than the threshold 
value of 36% CV, and 29%–76% of these subjects had 
  variability above the lower threshold of 28.05% CV . In contrast, 
100% of subjects in cluster 4 and in the “Others” category had 
Cmin variability above these variability thresholds.
Percentage of days below the cyclosporine 
Cmin target range by simulated adherence 
cluster
Figure 6 shows the percentage of days below the cyclosporine Cmin 
floor value of 100 ng/mL for the simulated   adherence   clusters. 
Again, the distributions of clusters 1–3 were similar, with mean 
(SD) values of 5.8 (4.9), 9.0 (5.0), and 6.5 (3.4) days, distinct 
from the mean (SD) value for cluster 4 of 76.8 (6.5) days, and 
the mean (SD) for “Others” of 38.3 (6.4) days. The proportion 
of subjects in clusters 1–3 for whom the serum concentration 
fell below 100 ng/mL (the lower limit of the target range) on 
more than 25% of treatment days was less than 1%, whereas the 
corresponding values for cluster 4 and the “Others” category 
were 100% and greater than 95%, respectively.
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defined by Kahan et al.4
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the metric was time below the cyclosporine therapeutic range 
or variability in cyclosporine exposure, and regardless of 
which measure of exposure was used (Cmin or Cavg).
The distributions of adherence patterns in clusters 1–4 fell 
into two sets, consisting of clusters 1–3 versus cluster 4. The 
distributions in clusters 1, 2, and 3 were similar, indicating 
that patients in clusters 2 and 3 can be placed in the same 
lower-risk category as the patients in cluster 1, even though 
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Figure 5 Simulated distribution of the coefficient of variation in cyclosporine Cmin 
for nonadherence clusters. Vertical dotted line: CV% threshold for Cmin of 36%, as 
defined by Kahan et al.4 Vertical dashed line: CV% threshold for Cmin of 28.05%, as 
defined by Waiser et al.5 
Abbreviations: Cmin, trough cyclosporine levels; CV%, coefficient of variation.
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Figure 6 simulated percentage of days below the cyclosporine Cmin target range for 
nonadherence clusters. Vertical solid line: 25% of days threshold separating clusters 
1–3 from cluster 4 and “Others”. 
Abbreviation: Cmin, trough cyclosporine levels.
Discussion
The results provide evidence that the proposed drug 
adherence-exposure model can be used to quantify the 
impact of nonadherence patterns on immunosuppressant 
exposure, and hence transplantation outcomes. The simulated 
distributions of adherence patterns closely matched those 
observed for patients in the study reported by Russell et al.9 
The distributions by adherence cluster were similar whether Therapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
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patients in clusters 2 and 3 sometimes were late or missed 
doses.9 The distributions for cluster 4 were distinct and 
shifted to the right (higher risk). The distribution of the 
“Others” category fell between those of clusters 1–3 and 4, 
and a vertical line dividing clusters 1–3 from cluster 4 and 
“Others” can be drawn. In Figure 6A, the threshold separating 
clusters 1–3 from cluster 4 and “Others” can be set at 25% 
of days below a serum level of 100 ng/mL. For the CV% 
for Cavg, the threshold of 28% determined by Kahan et al 
effectively separates clusters 1–3 from cluster 4 and “Others” 
(Figure 4).4 The thresholds for CV% for Cmin determined by 
Waiser et al and Kahan et al (28.05% and 36%, respectively) 
both fall within the 95% confidence interval (8.6%–39.6%) 
of values for cluster 1 (Figure 5),4,5 and a threshold of 50% 
better separates clusters 1–3 from cluster 4 and “Others” 
(Figure 5). The discrepancy between the 50% we propose 
and the 28.05%–36.00% proposed by Waiser et al and 
Kahan et al might represent experimental error or a difference 
in the thresholds applicable to different formulations of 
cyclosporine. We modeled the pharmacokinetics of the 
microemulsion formulation of cyclosporine, whereas the 
thresholds reported by Kahan et al and Waiser et al were 
determined in the 1990s for a different formulation.4,5
These results suggest that a dichotomy between adherers 
and nonadherers can be objectively defined by adherence-
simulation pharmacokinetic modeling based on MEMS data. 
Patients fitting the characteristics of cluster 4 and “Others” 
can be identified by their adherence patterns and targeted for 
intervention to improve adherence. This modeling approach 
can be applied to other oral immunosuppressants and oral 
medications for chronic conditions. The current standard 
of care for immunosuppression after renal transplantation 
is tacrolimus, a calcineurin inhibitor similar to cyclosporine 
in its pharmacokinetic profile that shows marked within-
patient variability in absorption.1 The values of the variables 
in the pharmacokinetic algorithm for cyclosporine will 
need to be modified to apply the model to tacrolimus. 
The simulated adherence patterns apply to twice-daily 
oral immunosuppressive regimens, including tacrolimus. 
In the study reported by Russell et al, 50% of patients took 
cyclosporine in different formulations, 41% took tacrolimus, 
and 9% took mycophenolate mofetil.9 It is conceivable 
that the adherence clusters differ for cyclosporine and 
tacrolimus because adherence is affected by the specifics 
of the regimen,12 ie, the drug type (the individual drug, 
formulation, route of administration), drug side-effects, 
and the number of daily doses.13 It is anticipated that the 
advent of novel immunosuppressants, new formulations, 
and different routes of administration will affect observed 
adherence patterns.
In summary, we have developed a drug adherence-
exposure model that: 1) accurately simulates observed patient 
adherence patterns; 2) computes values for drug exposure 
based on the pharmacokinetic properties of cyclosporine; 
3) quantifies the impact of nonadherence patterns on variability 
in cyclosporine levels; and 4) facilitates identification of 
patients likely to be at high risk of allograft rejection, a return 
to dialysis, and death. Results were consistent regardless 
of the specific exposure measure used. The proposed drug 
adherence-exposure model could be applied to other oral 
immunosuppressants, and to any oral drugs – with available 
MEMS data to identify high-risk patients who can be targeted 
for interventions aimed at enhancing medication adherence 
over the long term. This proposed model for identifying 
at-risk patients from their patterns of nonadherence should 
be tested in clinical studies.
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